Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Gastrointestinal 4Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Hematologic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1170Cisplatin 890Pemetrexed 845pembrolizumab 624Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
margetuximab × Thoracic × Clear all
NCT03219268 2023-12-21

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

MacroGenics

Phase 1 Completed
277 enrolled
BreastGastrointestinalGynecologicHead & NeckOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Hematologic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡